Feb 28 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* APPROVAL RECEIVED FOR PHASE II TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY
Feb 28 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* APPROVAL RECEIVED FOR PHASE II TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY